Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA

Omeros said the EMA’s CHMP issued a negative opinion on its marketing authorization application for narsoplimab to treat transplant-associated thrombotic microangiopathy (TA-TMA). The opinion followed re-examination of the committee’s original negative opinion, adopted in June 2026; the provided article text gives no additional figures or market reaction.

Analysis

The re-examination outcome removes a near-term route to European commercialization for narsoplimab in TA-TMA and weakens the value investors can assign to that indication. It does not, on the information provided, establish the status of any U.S. application, other indications, or Omeros’s broader pipeline. Nor does a CHMP opinion itself establish the European Commission’s final action; confirm the procedural next step and the full scientific rationale before underwriting a permanent loss of the opportunity.

Near term, expect pressure on OMER from reduced regulatory optionality and a higher perceived probability of further delay or failure. The more important 1–3 month catalysts are the company’s response, any appeal or resubmission path, and disclosure of the evidence gaps cited by regulators. Over 6–18 months, the impact depends on whether the program can generate data that address those concerns and whether Omeros has other assets or funding sources capable of supporting the business; the supplied information is insufficient to quantify either.

The contrarian risk is that a negative opinion after re-examination may already be reflected in the share price, while an eventual, credible path to resolve the objections could restore some option value. Conversely, treating this as an isolated EU setback may understate the risk if the rationale exposes broader efficacy or trial-design weaknesses. Do not extrapolate from this one indication to the whole company without reviewing the decision document, cash runway, and other program status.

Key Decisions for Investors

• Avoid buying the regulatory dip until the full CHMP rationale and procedural options are available. Track the European Commission’s next step and any company disclosure on whether concerns are addressable with existing data or require new studies.
• For event-driven books, consider a small, defined-risk bearish OMER position only if the stock has not already repriced the setback; avoid an unhedged, high-conviction short before checking the opening move, liquidity, borrow, and upcoming company catalysts. No price target is supportable from the supplied facts.
• Set a thesis-falsification alert for a documented, credible resubmission or appeal path supported by new evidence; that could reverse the regulatory-risk premium. A further delay, withdrawal, or evidence that the objections require substantial additional trials would reinforce the bearish view.
• Before sizing any position, verify Omeros’s cash runway, revenue dependence on this indication, status of other applications and programs, and the detailed CHMP objections. These missing data determine whether the event is a contained asset impairment or a broader balance-sheet and pipeline risk.